



Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

Downloaded from <https://aidsinfo.nih.gov/guidelines> on 8/31/2020

Visit the AIDS*info* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <https://aidsinfo.nih.gov/e-news>.

Appendix C. Clinical Trial Efficacy Data for Daily, Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis

Study ^a	Population	Regimen	Efficacy (95% CI)	Percentage of Participants with Detectable Plasma Levels of TFV
Partners PrEP (n = 4,758) ¹	Serodiscordant couples in Kenya and Uganda n = 1,579 randomized to receive TDF/FTC	TDF/FTC	75% (55% to 87%)	82% ^b
CDC TDF2 (n = 1,215) ²	Heterosexual men and women in Botswana	TDF/FTC	63% (22% to 83%)	79%
Fem-PrEP (n = 2,056) ³	Heterosexual women in South Africa, Kenya, and Tanzania	TDF/FTC	No effect	24%
VOICE (n = 5,029) ⁴	Heterosexual women in South Africa, Uganda, and Zimbabwe n = 1,003 randomized to receive TDF/FTC	TDF/FTC	No effect	29%

^a The data in this table are from studies that included heterosexual women.

^b Among the patients who achieved detectable plasma levels of TFV, the efficacy estimate for daily TDF/FTC was 91% (95% CI, 47% to 98%).⁴

Key: CI = confidence interval; FTC = emtricitabine; PrEP = pre-exposure prophylaxis TDF = tenofovir disoproxil fumarate; TFV = tenofovir

References

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med*. 2012;367(5):399-410. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22784037>.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med*. 2012. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22784038>.
3. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2012;367(5):411-22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22784040>.
4. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. *J Acquir Immune Defic Syndr*. 2014;66(3):340-348. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24784763>.